CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (the “Company”) announced today that it has commenced an underwritten public offering of 5,250,000 shares of its Class A common stock. All of the shares are being offered by Ironwood. The Company will grant the underwriters a 30-day option to purchase up to an additional 787,500 shares in connection with the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The final terms of the offering will be disclosed in a final prospectus supplement filed with the Securities and Exchange Commission (SEC).
